Insulinoma epidemiology and demographics: Difference between revisions

Jump to navigation Jump to search
Line 8: Line 8:
===Incidence===
===Incidence===
*The incidence of insulinoma is approximately 0.1-0.4 per 100,000 individuals that constitute 1-2% of all pancreatic neoplasms.<ref name="pmid23430217">{{cite journal |vauthors=Okabayashi T, Shima Y, Sumiyoshi T, Kozuki A, Ito S, Ogawa Y, Kobayashi M, Hanazaki K |title=Diagnosis and management of insulinoma |journal=World J. Gastroenterol. |volume=19 |issue=6 |pages=829–37 |year=2013 |pmid=23430217 |pmc=3574879 |doi=10.3748/wjg.v19.i6.829 |url=}}</ref><ref name="pmid1677058">{{cite journal |vauthors=Service FJ, McMahon MM, O'Brien PC, Ballard DJ |title=Functioning insulinoma--incidence, recurrence, and long-term survival of patients: a 60-year study |journal=Mayo Clin. Proc. |volume=66 |issue=7 |pages=711–9 |year=1991 |pmid=1677058 |doi= |url=}}</ref>
*The incidence of insulinoma is approximately 0.1-0.4 per 100,000 individuals that constitute 1-2% of all pancreatic neoplasms.<ref name="pmid23430217">{{cite journal |vauthors=Okabayashi T, Shima Y, Sumiyoshi T, Kozuki A, Ito S, Ogawa Y, Kobayashi M, Hanazaki K |title=Diagnosis and management of insulinoma |journal=World J. Gastroenterol. |volume=19 |issue=6 |pages=829–37 |year=2013 |pmid=23430217 |pmc=3574879 |doi=10.3748/wjg.v19.i6.829 |url=}}</ref><ref name="pmid1677058">{{cite journal |vauthors=Service FJ, McMahon MM, O'Brien PC, Ballard DJ |title=Functioning insulinoma--incidence, recurrence, and long-term survival of patients: a 60-year study |journal=Mayo Clin. Proc. |volume=66 |issue=7 |pages=711–9 |year=1991 |pmid=1677058 |doi= |url=}}</ref>
===Case-fatality rate===
*In [year], the incidence of [disease name] is approximately [number range] per 100,000 individuals with a case-fatality rate of [number range]%.
*The case-fatality rate of [disease name] is approximately [number range].
===Age===
===Age===
*Patients of all age groups may develop [disease name].
*Patients of all age groups may develop [disease name].

Revision as of 21:14, 10 September 2017

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Amandeep Singh M.D.[2]

Insulinoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Insulinoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Staging

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

X-ray

Ultrasound

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Insulinoma epidemiology and demographics On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Insulinoma epidemiology and demographics

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Insulinoma epidemiology and demographics

CDC on Insulinoma epidemiology and demographics

Insulinoma epidemiology and demographics in the news

Blogs on Insulinoma epidemiology and demographics

Directions to Hospitals Treating Insulinoma

Risk calculators and risk factors for Insulinoma epidemiology and demographics

Overview

Epidemiology and Demographics

Incidence

  • The incidence of insulinoma is approximately 0.1-0.4 per 100,000 individuals that constitute 1-2% of all pancreatic neoplasms.[1][2]

Age

  • Patients of all age groups may develop [disease name].
  • The incidence of [disease name] increases with age; the median age at diagnosis is [#] years.
  • [Disease name] commonly affects individuals younger than/older than [number of years] years of age.
  • [Chronic disease name] is usually first diagnosed among [age group].
  • [Acute disease name] commonly affects [age group].

Race

  • There is no racial predilection to [disease name].
  • [Disease name] usually affects individuals of the [race 1] race. [Race 2] individuals are less likely to develop [disease name].

Gender

  • Females are more commonly (60-75%)[2] affected by insulinoma than males. The female to male ratio is approximately 3:2.

Region

  • The majority of [disease name] cases are reported in [geographical region].
  • [Disease name] is a common/rare disease that tends to affect [patient population 1] and [patient population 2].

Developed Countries

Developing Countries

References

  1. Okabayashi T, Shima Y, Sumiyoshi T, Kozuki A, Ito S, Ogawa Y, Kobayashi M, Hanazaki K (2013). "Diagnosis and management of insulinoma". World J. Gastroenterol. 19 (6): 829–37. doi:10.3748/wjg.v19.i6.829. PMC 3574879. PMID 23430217.
  2. 2.0 2.1 Service FJ, McMahon MM, O'Brien PC, Ballard DJ (1991). "Functioning insulinoma--incidence, recurrence, and long-term survival of patients: a 60-year study". Mayo Clin. Proc. 66 (7): 711–9. PMID 1677058.

Template:WH Template:WS